

# State of Oklahoma SoonerCare

### **Intravenous Iron Therapy Prior Authorization Form**

Member Name:	Date of Birth:	Member ID#:
	Drug Informatio	on
Medication Name:		Strength:
Dose:	Regimen:	Start Date:
	Billing Units Per Dose:	
	Billing Provider Infor	
Provider NPI:	Provider Name:_	
Provider Phone:	Provider Fax:	
	Prescriber Informa	ation
Prescriber NPI:	Prescriber Name.	<i>:</i>
Prescriber Phone:	Prescriber Fax:	
	Criteria	
<ol> <li>Please indicate the dilection of the properties of th</li></ol>	Anemia with Chronic Kidney Disease with Heart Failure [Injectafer* (ferric carboxymatic kidney disease, please provide the following in chronic kidney disease:  mber on dialysis? Yes No nosis includes iron deficiency anemia, please sure addition to hemoglobin or complete blood count). If a trial of oral iron therapy? Yes No blease provide the following: It is of the oral iron therapy trial: It is of the oral iron therapy trial: It is of the oral iron therapy: It is of the oral iron therap	altose) requests only]  Information:  Ibmit laboratory results verifying iron deficiency and only.  Is ant reason why oral iron therapy is not appropriate for
6. Has the member had a. If "Yes", p i. Nam ii. Date iii. Mem	per:	sucrose)? Yes No
	(Page 1 of 2)	

#### DETUDN TO:

### PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

### **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 118 8/29/2023



# State of Oklahoma SoonerCare

## **Intravenous Iron Therapy Prior Authorization Form**

Member l	Name:	Date of Birth:	Member ID#:	
		Criteria		
7. For Inj	ectafer <sup>®</sup> , if the member has i	ron deficiency with heart failure, please	e provide the following additional informat	tion:
A.	Does the member have Ne	w York Heart Association class II-III he	eart failure? Yes No	
B.	Will IV Iron therapy be used	d to improve exercise capacity? Yes	No	
C.	Is the member receiving op	timal background therapy for Heart Fa	illure? Yes No	
		ventricular ejection fraction (LVEF) <4		
E.	Member's current weight: _	Hemoglobin (Hb) (g/dl	L): Date taken:	
F.	Please submit laboratory re	esults verifying iron deficiency.		
G.		weeks 12, 24, and 36, please submit usequests will be approved for (1) 500m	updated lab results verifying continued iroug dose at a time.	n
**P	lease note: Infed <sup>®</sup> (iron de	ktran) and Venofer <sup>®</sup> (iron sucrose) a	re available without prior authorization	n**
Additional				
		(Page 2 of 2)		
Prescribe	er Signature:		Date:	
l <b>certify tha</b> Pease do no	<b>It the indicated treatment is m</b> ot send in chart notes. Specific i	edically necessary and all information in nformation will be requested if necessary.	s true and correct to the best of my knowled Failure to complete this form in full will result in	<b>edge.</b> in

### PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

processing delays.

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

#### **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 118 8/29/2023